SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-25-004547
Filing Date
2025-01-10
Accepted
2025-01-10 17:23:08
Documents
16
Period of Report
2025-01-10
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d917502d8k.htm   iXBRL 8-K 31910
2 EX-1.1 d917502dex11.htm EX-1.1 156896
3 EX-5.1 d917502dex51.htm EX-5.1 6973
7 GRAPHIC g917502g0111012046486.jpg GRAPHIC 2644
  Complete submission text file 0001193125-25-004547.txt   367263

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA amlx-20250110.xsd EX-101.SCH 2847
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE amlx-20250110_lab.xml EX-101.LAB 17235
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE amlx-20250110_pre.xml EX-101.PRE 10810
18 EXTRACTED XBRL INSTANCE DOCUMENT d917502d8k_htm.xml XML 3505
Mailing Address 43 THORNDIKE STREET CAMBRIDGE MA 02141
Business Address 43 THORNDIKE STREET CAMBRIDGE MA 02141 617-683-0917
Amylyx Pharmaceuticals, Inc. (Filer) CIK: 0001658551 (see all company filings)

IRS No.: 464600503 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41199 | Film No.: 25523997
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)